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Infl  ammatory bowel disease (IBD) is a chronic 
idiopathic infl  ammation of the gastrointestinal 
tract that manifests as ulcerative colitis and 
Crohn’s disease in human. These pathologies 
exemplify the rupture of equilibrium between 
bacterial-driven infl  ammation and tolerogenic 
gut immunity (1–3). In healthy individuals, the 
intestinal mucosa is in a state of controlled in-
fl  ammation and its homeostasis depends upon 
intimate contacts between innate immune and 
epithelial cells. Dendritic cells and macrophages 
participate in the early detection of infl  amma-
tory stress and trigger destructive responses as-
sociated with colitis. However, because of their 
frontline position, intestinal epithelial cells 
(IECs) likely play a key role in stress sensing. 
They are known to express Toll-like receptors 
and MHC molecules and to secrete antibacte-
rial peptides and chemokines upon activation. 
It is therefore important to evaluate the hierar-
chical contribution of epithelial cells to stress 
sensing and triggering of gut infl  ammation.
Vanin-1 is an ectoenzyme anchored at the 
surface of epithelial cells by a glycosylphospha-
tidyl inositol moiety (4, 5). Its pantetheinase 
activity is involved in the metabolic pathway 
of pantothenate (vitamin B5) and is a main 
provider of cysteamine to tissues (5). In Vanin-1–
defi   cient mice, the lack of detectable tissue 
cysteamine is associated with an enhanced 
γ-gluthamylcysteine synthetase activity leading 
to elevated endogenous glutathione (GSH) stores 
in tissues. This confers on Vanin-1−/− animals 
a better resistance to oxidative stress exposure 
that can be abolished by administration of cys-
tamine (the disulfi  de form of cysteamine) (6, 7). 
As a consequence, Vanin-1−/− mice display a 
down-regulated tissue infl  ammation in  response 
to systemic oxidative stress. In gut, oxidative 
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Colitis involves immune cell–mediated tissue injuries, but the contribution of epithelial cells 
remains largely unclear. Vanin-1 is an epithelial ectoenzyme with a pantetheinase activity 
that provides cysteamine/cystamine to tissue. Using the 2,4,6-trinitrobenzene sulfonic acid 
(TNBS)-colitis model we show here that Vanin-1 defi  ciency protects from colitis. This 
protection is reversible by administration of cystamine or bisphenol A diglycidyl ether, 
a peroxisome proliferator-activated receptor (PPAR)𝗄 antagonist. We further demonstrate 
that Vanin-1, by antagonizing PPAR𝗄, licenses the production of infl  ammatory mediators 
by intestinal epithelial cells. We propose that Vanin-1 is an epithelial sensor of stress 
that exerts a dominant control over innate immune responses in tissue. Thus, the Vanin-1/
pantetheinase activity might be a new target for therapeutic intervention in 
infl  ammatory bowel disease.
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stress can be generated by acute exposure to nonsteroidal anti-
infl  ammatory drugs or chronic Schistosoma mansoni infection. 
In both situations, Vanin-1−/− mice were shown to control 
the resulting infl   ammation and ensuing hemorrhages that 
normally provoke death (7). Collectively, these observations 
pointed to a proinfl  ammatory role of Vanin-1, which may be 
involved in the development of IBDs. These pathologies re-
sult from an excessive immune response to gut-derived infec-
tious stimuli in a context of unbalanced immune tolerance. 
Therefore, we investigated an experimental model of colitis 
after intrarectal administration of 2,4,6-trinitrobenzene sul-
fonic acid (TNBS) (8). This model has been widely used to 
dissect some of the molecules and the cellular mechanisms 
involved in acute or chronic colitis. Among them, the 
peroxisome proliferator-activated receptor (PPAR)γ was 
identifi  ed as a checkpoint in the control of antiinfl  ammatory 
responses and gut homeostasis (9, 10). Indeed, PPARγ+/− 
heterozygous mice exhibit increased susceptibility to experi-
mental TNBS-colitis, and in human, ulcerative colitis   patients 
display an impaired expression of PPARγ in colonic epithe-
lial cells (11, 12). In addition, ligand activation of PPARγ 
was shown to reduce the severity of colitis in mouse models, 
and it was recently demonstrated that the positive clinical ef-
fect of 5-aminosialicylic acid in the treatment of IBD patients 
was linked to PPARγ activation (13, 14). PPARγ is a mem-
ber of the steroid receptor family with various biological 
functions including diff  erentiation, apoptosis, lipid metabo-
lism, and antiinfl  ammatory properties (15, 16). Ligands for 
PPARγ include few identifi  ed natural compounds like poly-
unsaturated fatty acids, some eicosanoids, the 15-deoxy-
∆12,14-prostaglandin J2 (15-d-PGJ2), and certain drugs like the 
thiazolidinedione (17–20). After activation, PPARγ forms 
heterodimer with the retinoic X receptor and the resulting 
complex binds PPAR-responsive elements (PPREs) within 
target gene promoters (15). Here we show that Vanin-1 
modulates both the expression and the ligand-induced acti-
vation of PPARγ in epithelial cells, therefore, regulating the 
expression of downstream proinfl   ammatory target genes. 
Control of PPARγ gene expression and function explains 
why Vanin-1 mutant mice better resist to colitis. These stud-
ies further show the importance of Vanin-1–dependent epi-
thelium-derived signals in the triggering of colitis.
RESULTS
Vanin-1−/− mice resist colitis-causing death: 
an epithelial-based mechanism
Mice were subjected to TNBS-induced colitis which pro-
voked a rapid weight loss and death of 80% control BALB/c 
mice within 10 d (Fig. 1, A and B). In contrast, 70% of the 
Vanin-1−/− mice survived during the same period and did 
not show considerable weight loss. Since Vanin-1 controls 
the production of cysteamine in vivo, we administered  cystamine 
(120 mg/kg) 2 d before TNBS injection and daily until death 
or sacrifi  ce. This treatment completely reversed the protec-
tion conferred by the lack of Vanin-1 toward colitis since 
90% of cystamine-treated Vanin-1−/− mice died within 5 d 
(Fig. 1 A). Thus, cystamine restores the WT-like suscepti-
bility to TNBS-induced colitis in Vanin-1−/− mice.
Figure 1.  Protection of Vanin-1−/− mice from colitis-causing 
death: an epithelial-based mechanism. (A) Survival rates of untreated 
or cystamine-treated BALB/c control or Vanin-1−/− mice after administra-
tion of TNBS. The number of mice is indicated. (B) Comparative weight loss 
during TNBS-colitis between control and Vanin-1−/− mice. (C) Survival at 
day 5 of bone marrow chimeric mice after induction of colitis. The geno-
type of donors and recipients is indicated. (D) Survival rates of immunode-
fi  cient BALB/c SCID and Vanin-1−/− SCID mice to TNBS-induced colitis.JEM VOL. 203, December 25, 2006  2819
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Under normal conditions, Vanin-1 is predominantly ex-
pressed by epithelial but not hematopoietic cells. To defi  ni-
tively establish the major contribution of epithelial cells in 
the control of colitis, we generated chimeras by reconstitut-
ing BALB/c control or Vanin-1−/− irradiated mice with WT 
or Vanin-1−/− Thy1-depleted bone marrows. These chi-
meric animals were subsequently submitted to TNBS-
induced colitis and their survival was checked over 5 d. As 
shown in Fig. 1 C, Vanin-1−/− recipients displayed a consider-
ably reduced mortality rate independently of the genotype of 
the grafted bone marrow. Indeed,  40–50% Vanin-1−/− 
versus 0–10% control mice survived. Because the diff  erential 
sensitivity to colitis might refl  ect the impact of the Vanin-1 
mutation on the development of gut lymphocytes, we intro-
duced the Vanin-1 mutation on the severe combined immu-
nodefi  cient (SCID) mouse background. As shown in Fig. 
1 D, although the lack of lymphocytes was associated with 
a reduced mortality, Vanin-1–defi  cient SCID BALB/c mice 
better resisted TNBS-colitis compared with Vanin-1+/+ 
SCID controls.
Thus, the protection conferred by the absence of Vanin-1 
against lethal TNBS-colitis depends on a primordial epithe-
lial-based response. These results document the preponderant 
role played by epithelial cells in the control of the severity of 
the colitis.
Lack of Vanin-1 is associated with mild tissue damage 
after colitis induction
The colon of mice was examined 2 d after TNBS injection, 
and the severity of clinical signs of colitis was evaluated mac-
roscopically using the Wallace score. As shown in Fig. 2 A, 
control mice had severe macroscopic lesions characterized by 
numerous hemorrhagic and necrotic zones widely distributed 
along the whole colon and extending into the cecum cor-
responding to a Wallace score of 8 (Fig. 2 B). In contrast, 
Vanin-1−/− colons remained relatively healthy (Wallace 
score   4).
Histologically, TNBS-treated WT colons were charac-
terized by a severely disrupted mucosa with large areas 
of ulceration and extensive necrosis sparing few glands, 
subepithelial edema, and dense infl  ammatory infi  ltrate (Fig. 
2 C). In contrast, the improved survival of Vanin-1−/− mice 
was correlated to considerably less alterations of the colon 
with preserved mucosa integrity, reduced submucosal edema, 
and poorer leukocyte infi   ltration. This was quantifi  ed  on 
several TNBS-treated animals using the Ameho score and 
represented in Fig. 2 D. As expected, cystamine-treated 
Vanin-1−/− mice showed similar alterations to that observed 
in control animals (Fig. 2). These results demonstrate that 
Vanin-1 defi  ciency in the epithelial compartment prevents 
massive tissue infi  ltration by infl  ammatory cells and conse-
quently the development of colonic lesions.
Vanin-1 controls the infl  ammatory response 
in injured colon
To further document the impact of Vanin-1 defi  ciency on 
colitis we scored the production of infl  ammatory eff  ectors in 
colon of mice killed 2 d after TNBS injection. Using a cytokine 
array (Fig. 3, A and B), we observed the induction of a 
particular set of cytokines and chemokines in the colons of 
WT mice compatible with a major infl  ammatory reaction. 
This set includes the proinfl  ammatory cytokine IL-6 tissue 
inhibitor of metalloproteinase-1, involved in tissue  remodeling 
and wound healing, the neutrophil chemoattractant macro-
phage infl  ammatory protein (MIP)-2 and keratinocyte che-
moattractant, and MIP-1α and monocyte   chemoattractant 
Figure 2.  Reduced tissue damage in Vanin-1−/− colons after colitis 
induction: cystamine restores the susceptibility to TNBS-driven 
  colitis in Vanin-1−/− mice. (A) Morphologic examination of colons of 
TNBS-treated BALB/c control mice and Vanin-1−/− animals receiving or not 
receiving a treatment with cystamine. (B) The severity of the colon injury 
was evaluated using the macroscopic Wallace score. (C) Representative 
histological sections of colon tissues of TNBS-treated control, Vanin-1−/−, 
and cystamine-treated Vanin-1−/− mice. (D) The severity of the lesions was 
evaluated using the histological Ameho score. The number of mice is indi-
cated. All of these analyses were performed 2 d after TNBS administration.2820   VANIN-1 LICENCES GUT INFLAMMATION | Berruyer et al.
protein (MCP)-1, known to control macrophage recruit-
ment. In contrast, Vanin-1−/− tissue extracts presented only 
low levels of these infl  ammatory mediators (Fig. 3, A and B). 
Similarly, we found a lower induction of cyclooxygenase 
(COX)-2 expression in TNBS-treated Vanin-1−/− than WT 
colons (Fig. 3, C and D). COX-2 is an inducible enzyme that 
catalyzes prostaglandin synthesis acting as potent lipid infl  am-
matory mediators. Accordingly, as shown by Western blot 
analysis, cystamine administration boosted COX-2 expression 
in TNBS-treated Vanin-1−/− colons (Fig. 3 D).
These fi  ndings demonstrate that Vanin-1 regulates the 
production of infl  ammatory signals in an injured colon. This 
explains the modest leukocyte recruitment in TNBS-treated 
Vanin-1−/− colons which was further confi   rmed by fl  ow 
cytometry analysis of Mac1high-F4/80+ macrophages and 
Mac-1lowGr1+ granulocytes obtained from dissociated tissues 
(unpublished data).
Bisphenol A diglycidyl ether, a PPAR𝗄 antagonist, abrogates 
Vanin-1−/− protection against colitis
PPARγ activation by agonists exerts antiinfl  ammatory eff  ects 
and attenuates TNBS-colitis (11, 21). This incited us to de-
termine whether PPARγ contributed to the down- regulation 
of the infl  ammatory processes observed in TNBS-treated 
Vanin-1−/− mice. This was investigated by daily intraperi-
toneal administration of the bisphenol A diglycidyl ether 
(BADGE) PPARγ antagonist (30 mg/kg), starting 2 d before 
TNBS injection (22, 23). All BADGE-treated mice developed 
a severe colitis to a level comparable to that of TNBS-
exposed BALB/c mice. In Vanin-1−/− mice, BADGE adminis-
tration restored the sensitivity to TNBS-colitis recapitulating 
typical colon lesions with high infl  ammatory cell infi  ltrates 
and necrotic lesions (Fig. 4, A–C). This was not caused 
by an intrinsic toxicity of BADGE itself because mice sub-
mitted to an injection of BADGE alone, without intra  rectal 
TNBS administration, did not die or present sign of   colonic 
damage over the 15 d of experimentation (unpublished data). 
These fi  ndings suggested that the protective phenotype asso-
ciated with the Vanin-1 defi  ciency was fully abrogated by 
PPARγ inactivation.
Vanin-1 regulates the expression of PPAR𝗄 
in epithelial cells
Because BADGE suppresses the resistance of the Vanin-1−/− 
mice to TNBS-induced infl  ammation, we explored whether 
the Vanin-1 molecule directly regulated PPARγ expression 
and/or activation. First, despite high variability between ani-
mals we did not fi  nd a considerable diff  erence in PPARγ 
protein expression between control and Vanin-1−/− mice by 
Western blot analysis on whole colon tissue extracts (Fig. 
4 D). After TNBS administration, a comparable increase in 
PPARγ expression was observed in WT and Vanin-1−/− 
  colons (Fig. 4 D). In Vanin-1−/− mice, cystamine administra-
tion, which abrogates protection against colitis only slightly, 
reduced PPARγ levels, whereas BADGE administration had 
no impact. Thus, on whole colon extracts, PPARγ expres-
sion did not correlate with the clinical outcome. Further-
more, BADGE treatment, despite its antagonistic eff  ect, did 
not seem to modulate PPARγ expression. A major diffi   culty 
in this type of analysis is caused by the largely distributed 
PPARγ expression among numerous cell types in colon, 
whereas Vanin-1 expression is mostly restricted to epithelial 
cells. Therefore, we performed the same analysis on protein 
lysates obtained from purifi   ed resting IECs, which show 
considerably higher PPARγ expression levels in Vanin-1−/− 
compared with control IECs (Fig. 4 E). Because of the toxic-
ity of TNBS administration, we were unable to obtain 
enough viable purifi  ed IECs from TNBS-treated mice to be 
able to perform the same analysis.
Figure 3.  Vanin-1 controls the infl  ammatory response in injured 
colon. (A) ELISA-based cytokine arrays were hybridized with total colon 
tissue lysates derived from control or Vanin-1−/− mice 2 d after colitis 
induction. Relevant signals are indicated. (B) Quantifi  cation of signal in-
tensities resulting from the cytokine array experiment. (C) Comparative 
Western blot analysis of the expression of COX-2 in total colon extracts 
from control and Vanin-1−/− mice before and 2 d after TNBS administra-
tion. Quantifi  cation of the results is represented in the bottom panel. 
(D) Similar experiment including total colon extracts from Vanin-1−/− mice 
submitted to a treatment with cystamine. Quantifi  cation is shown in the 
bottom panel.JEM VOL. 203, December 25, 2006  2821
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We then turned to similar analyses on two distinct 
cell lines. The mouse MTE4.14 thymic epithelial cell line 
naturally expresses Vanin-1. Using a lentiviral-based RNA 
  interference strategy, we derived clones showing an 80% 
reduction of Vanin-1 cell surface expression (named Vanin-
1RNAi MTE4.14 cells). In parallel, the immature mouse 
intestinal cell line mIC, which lacks Vanin-1 expression, 
was transfected with Vanin-1 cDNA to generate stable 
Vanin-1(+) mIC transfectants. As shown in Fig. 5, the 
  absence or reduced level of Vanin-1 was systematically asso-
ciated with an up-regulation of the PPARγ mRNA, quan-
tifi  ed by real-time PCR. Indeed, levels of PPARγ mRNA 
were, respectively eight- and fi  vefold higher in the Vanin-
1RNAi MTE4.14 and the Vanin-1(−) mIC cells than in 
their Vanin-1(+) counterparts (Fig. 5 A). This was corre-
lated with changes in PPARγ protein level and measured 
by Western blot analysis (Fig. 5 B). The augmented PPARγ 
mRNA expression could be reversed by incubating Vanin-
1RNAi MTE4.14 cells with 1 nM cystamine for 12 h 
(Fig. 5 C). The prostaglandine 15-d-PGJ2 has been iden-
tifi  ed as a potent endogenous ligand of PPARγ that also 
increases PPARγ mRNA expression in cell lines (24, 25). 
We found using real-time PCR that 15-d-PGJ2 (5 μM) 
boosted PPARγ mRNA expression in Vanin-1(+) MTE4.14 
cells by sixfold but did not further augment that found 
in Vanin-1RNAi MTE4.14 where the level of PPARγ 
expression was already high (Fig. 5 D). In conclusion, 
we document a reverse relationship between Vanin-1 and 
PPARγ transcript levels and an impact of cystamine on 
PPARγ transcription.
The activation of PPAR𝗄 is modulated by Vanin-1 
in epithelial cells
Activation of PPARγ results in the translocation of the pro-
tein into the nucleus and its subsequent binding to specifi  c 
DNA elements called PPREs (15). We investigated whether 
Vanin-1 could modulate the degree of PPARγ activation 
by analyzing the intracellular distribution of a GFP-tagged 
PPARγ molecule transfected in the mIC cells. In unstimu-
lated cells, the localization of the fl  uorescent tag was pre-
dominantly cytoplasmic. Exposure of cells to 15-d-PGJ2 (5 μM) 
for 12 h provoked a considerable nuclear translocation of 
the GFP-tagged PPARγ in Vanin-1(−) but less so in Vanin-
1(+) mIC cells (Fig. 6 A). To quantify this parameter, we 
  investigated PPARγ transcriptional activity by transient 
transfection of a 3XPPRE-luciferase reporter construct in 
MTE4.14 cells. As already reported in other cellular models 
(26, 27), 15-d-PGJ2 induced a threefold increase of the 
  reporter-gene activity in Vanin-1(−) cells. In contrast, this 
treatment had no detectable eff  ect in Vanin-1(+) mIC cells 
(Fig. 6 B). Given the modest level of PPRE-mediated tran-
scription in control cells, we combined PPARγ ligands with 
a retinoic acid receptor agonist (i.e., all trans-retinoic acid 
[ATRA]) previously shown to enhance the PPARγ-dependent 
eff  ects and to induce maturation of myelomonocytic cells (28). 
In MTE4.14 epithelial cells, this combination considerably 
amplifi  ed the detectable reporter-gene activity in the Vanin-
1(−) cells. In contrast, in Vanin- 1(+) cells the reporter gene 
activity was still barely detectable (Fig. 6 B). This shows that 
the presence of the Vanin-1 molecule prevents the activation 
of PPARγ in response to agonists.
Figure 4.  BADGE abrogates the protection against colitis 
associated with Vanin-1 defi  ciency. (A) Comparative survival rates of 
untreated and BADGE-treated control and Vanin-1−/− mice during 
TNBS-colitis. (B) Macroscopic appearance of colons from BADGE-treated 
control and Vanin-1−/− mice 2 d after TNBS induction. (C) Representative 
histological colon sections 2 d after TNBS administration. (D) Western blot 
analysis of the PPARγ expression in total colon extracts from control, 
Vanin-1−/− mice, and Vanin-1−/− animals treated with cystamine or 
BADGE. Samples were prepared 2 d after TNBS induction. The bottom 
panel represents a quantifi  cation of the results. (E) Western blot analysis 
of the expression of the PPARγ protein by IEC purifi  ed from control or 
Vanin-1−/− colons. Quantifi  cation is shown in the bottom panel.2822   VANIN-1 LICENCES GUT INFLAMMATION | Berruyer et al.
Vanin-1 regulates IL-1𝗃–driven chemokine release 
by epithelial cells via modulation of PPAR𝗄 activation
To demonstrate that Vanin-1 acts autonomously at the level 
of epithelial cells, we extended in vitro our analysis. We then 
showed by real-time quantitative PCR analysis that IL-1β 
(10 ng/ml), a potent proinfl  ammatory stimulus, induced 
the production of MCP-1 and MIP-2 in the Vanin-1(+) 
MTE4.14 or mIC cells, but not in their Vanin-1(−) counter-
parts (Fig. 7). A similar result was observed with COX-2 in 
mIC cells (unpublished data). Therefore, Vanin-1 expression 
licenses the epithelial cell response to a proinfl  ammatory 
stimulus through the specifi  c transcription of target genes.
To demonstrate further that PPARγ is a main target of 
Vanin-1 proinfl  ammatory activity, we evaluated the eff  ect of 
PPARγ agonists and antagonists on the production of the 
MCP-1 or MIP-2 chemokines by Vanin-1(+) or (−) cells 
(Fig. 7). Stimulation of the Vanin-1(+) cell lines (MTE4.14 
and mIC transfectants) by IL-1β (10 ng/ml for 12 h) resulted 
in the transcription of MCP-1 or MIP-2 mRNAs (approxi-
mately threefold increase), which was abrogated by the 
simultaneous incubation with the PPARγ agonist 15-d-PGJ2 
(5 μM). Interestingly, the defi  ciency in chemokine produc-
tion by IL-1β–stimulated Vanin-1(−) cells (RNAi MTE4.14 
or mIC) was almost fully restored by antagonizing PPARγ 
activation with BADGE (5 μM). Hence, modulation of 
PPARγ activation by agonists and antagonists infl  uenced the 
Figure 5.  Vanin-1 regulates the expression of PPAR𝗄 in epithelial 
cells. (A) Real-time PCR analysis of the expression of the PPARγ mRNA 
by Vanin-1(+) and Vanin-1(−) MT4.14 or mIC cells. (B) Western blot 
analysis of the expression of the PPARγ protein in lysates from the Vanin-
1(+) (control) and Vanin-1RNAi MT4.14 cells. Quantifi  cation is shown in 
the bottom panel. (C) Real-time PCR measurement of PPARγ expression 
in untreated or cystamine-treated MTE4.14 cells. (D) Real-time PCR analy-
sis of PPARγ expression in MTE4.14 cells treated or not treated with 
15-d-PGJ2.
Figure 6.  PPAR𝗄 activation is modulated by the expression of 
Vanin-1 by epithelial cells. (A) Intracellular localization of a GFP-
tagged-PPARγ in Vanin-1(−) control or Vanin-1(+)–transfected mIC 
cells. Untreated cells (NT) and cells incubated with 15-d-PGJ2 are shown. 
The distribution of the fl  uorescent tag was examined under a fl  uorescent 
microscope. In the merged images, green represents PPARγ-GFP, whereas 
blue represents the nucleus staining performed with DAPI. PPARγ can be 
seen to translocate into the nucleus after 15-d-PGJ2 treatment most 
markedly in Vanin-1(−) cells. (B) Vanin-1(+) control and Vanin-1RNAi 
MTE4.14 cells were transfected with the PPRE-driven luciferase reporter 
vector 3X-PPRE-luc. Promoter activity was determined in untreated cells 
(NT) or after exposure of the cells to 15-d-PGJ2 or a combination of 
15-d-PGJ2 with ATRA.JEM VOL. 203, December 25, 2006  2823
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Vanin-1–dependent cellular response to proinfl  ammatory 
stimuli. This shows that Vanin-1 acts upstream of PPARγ in 
a pathway controlling the production of infl  ammatory signals 
by epithelial cells.
DISCUSSION
In healthy individuals, the gut buff  ers the constant low level of 
environmental stress originating from the diet and the conven-
tional microfl  ora. A normal epithelium provides an eff  ective 
barrier against luminal agents. When the integrity of the bar-
rier is compromised, however, innate mechanisms of defense 
are triggered to eliminate the danger, repair the tissue, and 
restore a homeostatic state. In this study, we have addressed 
the role of the epithelial enzyme Vanin-1 in the development 
of colitis and show that Vanin-1 defi  ciency reduces colitis 
severity in the TNBS model. This is clearly demonstrated by 
an improved survival of Vanin-1−/− mice compared with WT 
animals after TNBS treatment. Furthermore, treatment of 
these mice by a PPARγ antagonist (BADGE) abrogates their 
protection against TNBS-colitis. Thus, Vanin-1 appears to 
control TNBS-colitis by antagonizing PPARγ activity.
Vanin-1 regulates oxidative stress in the gut
Vanin-1 is an epithelial ectoenzyme that provides cysteamine 
to tissue through the hydrolysis of pantetheine, a vitamin B5 
intermediate. In mice, Vanin-1 defi  ciency confers resistance 
to systemic oxidative stress associated with ionizing radiations 
or exposure to xenobiotics (6). Thus, Vanin-1 participates in 
the response to stress in vivo. In gut, Vanin-1 is expressed by 
epithelial but not hematopoietic cells. We previously re-
ported that Vanin-1−/− gut shows increased levels of endog-
enous GSH and that Vanin-1–defi  cient mice are protected 
against acute intestinal damages induced by oxidative stress 
associated with Schistosoma mansoni infection or indomethacin 
administration (7).
In the murine model of colitis, TNBS administration 
engenders oxidative stress through its metabolism by de-
pleting GSH and generating reactive oxygen species (29). 
Overproduction of reactive oxygen species by immune cells 
contributes to tissue injuries observed in colitis, and a muco-
sal GSH defi  ciency is observed in IBD (30–32). This defi  cit 
is mainly caused by the decreased activities of key enzymes 
in GSH synthesis like γ–glutamylcysteine synthetase and 
γ−glutamyltransferase (32, 33). In contrast, antioxidant ther-
apy with N-acetylcysteine, a GSH precursor, attenuates the 
acute colitis through increased mucosal GSH levels (33, 34). 
Thus, impaired mucosal antioxidant capacity may further 
promote oxidative damage, whereas increased mucosal an-
tioxidant activity prevents oxidative damage. This might ex-
plain the better survival and the mild infl  ammatory response 
of Vanin-1−/− mice after induction of colitis by TNBS.
Vanin-1 regulates epithelial cell-driven infl  ammation
Invasion of the mucosa by leukocytes is a characteristic of the 
gut infl  ammation. The role of the IECs in orchestrating this 
recruitment is however not clearly defi  ned. In vitro, epithe-
lial cell lines respond to proinfl  ammatory signals by secreting 
cytokines and chemokines. In vivo, specifi  c alteration of the 
intestinal epithelium was shown to lead to intestinal infl  am-
mation (35, 36) and the functional role of epithelium-secreted 
chemokines was demonstrated by targeting overexpression of 
MIP-2 in IECs using a transgenic model (37).
We report herein that the absence of Vanin-1 results in a 
dramatic decrease in the expression of a wide panel of infl  am-
matory cytokines in the colon after TNBS. Consequently, 
Vanin-1−/− mice exhibit attenuated myeloid cell recruitment 
and lowered subsequent tissue damage. Using bone marrow–
reconstituted chimeras, we defi   nitively show that the de-
creased susceptibility of Vanin-1−/− mice to experimentally 
induced colitis was determined at the epithelial level. These 
fi  ndings indicate that IECs may actively alter mucosal im-
mune response.
The TNBS-colitis model is usually considered as a Th1-
driven infl  ammatory model recapitulating clinical aspects of 
the human Crohn’s disease. However, several arguments 
highlight the importance of innate immunity in the develop-
ment of colitis: (a) in human IBD as in mouse experimental 
models, recruitment and activation of macrophages is a con-
stant feature of the immunopathology; (b) mice devoid of 
Stat3 specifi   cally in macrophages and neutrophils develop 
chronic enterocolitis (38); (c) murine colitis is dependent on 
Figure 7.  Modulation of PPAR𝗄 activation refl  ects Vanin-1–
  dependent control of chemokine release by epithelial cells. (A) Real-
time PCR exploration of the expression of the MCP-1 mRNAs in Vanin-1(+) 
control and Vanin-1RNAi MTE4.14 cells. Analyses were performed on un-
treated cells (NT) and cells stimulated with IL-1β alone or submitted to a 
coincubation of IL-1β together with 15-d-PGJ2 or BADGE. (B) A similar 
experiment was performed to investigate the expression of the MIP-2 
mRNA in Vanin-1(−) control and Vanin-1(+)–transfected mIC cells.2824   VANIN-1 LICENCES GUT INFLAMMATION | Berruyer et al.
continuous macrophage migration inhibitory factor produc-
tion by the nonlymphocyte immune system (39); (d) the 
α1-mediated inhibition of TNBS-colitis is accredited to 
monocytes as key α1β1 integrin-expressing cell type in-
volved in the eff  ector phase of intestinal infl  ammation (40); 
and (e) SCID mice submitted to TNBS develop colitis indi-
cating that this syndrome can be induced in the absence of 
lymphocytes, so that the disease can be driven by innate im-
mune mechanisms. Here we reported that Vanin-1−/− mice 
display a protection against colitis-causing death associated 
with an observable mild infi   ltration of macrophages and 
granulocytes in the colonic mucosa. In addition, Vanin-1−/− 
SCID mice exhibit the same protection. Collectively, all this 
clearly highlights the contribution of the IECs to the regula-
tion of the innate immune responses.
Vanin-1 regulates PPAR𝗄 in epithelial cells
PPARγ is a nuclear receptor activated by fatty acid ligands 
and involved in the control of the cellular response to meta-
bolic and nutritional signals (16). A broad recent study about 
PPARγ describes a key role of this nuclear factor in the 
maintenance of mucosal integrity in the intestine and a pow-
erful intestinal antiinfl  ammatory eff  ect (10, 41). PPARγ ago-
nists decrease the severity of colitis (9, 11). Thus, modulation 
of PPARγ has become of great interest for therapeutic strate-
gies in human IBD (42). PPARγ is expressed by several cell 
types in the colon, including hematopoietic cells like macro-
phages or lymphocytes and epithelial cells. The antiinfl  am-
matory function of PPARγ is attributed to a transcriptional 
attenuation of the expression of cytokines, chemokines, or 
COX-2 by these cells (9). Recently, it has been reported that 
targeted inactivation of PPARγ in colonic epithelial cells ab-
rogates its protective role in colitis (43), but the regulation of 
PPARγ in epithelial cells remains poorly understood.
One of our main results is that in vivo a functional PPARγ 
antagonist (BADGE) abrogates the protective phenotype of 
the Vanin-1−/− mice against colitis. This clearly positions 
PPARγ downstream of a Vanin-1 eff  ect. We next demon-
strated that in vivo the expression of PPARγ in IECs is mod-
ulated by the presence of Vanin-1 or the administration of 
cystamine. This was confi  rmed in vitro using in parallel cel-
lular models based on transfectants and RNA interference. 
The absence of Vanin-1 is correlated with an increase in 
PPARγ expression, whereas cysteamine down-regulates its 
expression. In addition, our results indicate that Vanin-1 di-
rectly aff  ects PPARγ activation. As shown using PPRE re-
porter assays, the activation of PPARγ by its natural agonist 
ligand 15-d-PGJ2 was improved in Vanin-1(−) epithelial 
cells compared with Vanin-1(+) counterparts, both at the 
level of nuclear translocation and transcriptional activity. On 
the other hand, we showed that Vanin-1(+) epithelial cells 
signifi  cantly respond to IL-1β proinfl  ammatory stimulation 
by expressing infl  ammatory genes including MCP-1, MIP-2, 
or COX-2. In addition, we showed that 15-d-PGJ2 consid-
erably antagonized the eff  ect of IL-1β by inhibiting the ex-
pression of these target genes in cells. A similar result was 
described for pancreatic stellate cells in which PPARγ acti-
vation by 15-d-PGJ2 results in the inhibition of inducible 
MCP-1 expression in IL-1β–stimulated cells (27). Of inter-
est, Vanin-1(−) cells do not respond to IL-1β stimulation, 
but in contrast, exposure of these cells to BADGE restored 
the cellular capacity to respond to the IL-1β proinfl  amma-
tory signal.
Conclusion
Collectively, these fi  ndings argue for a Vanin-1–dependent 
regulation of the function of PPARγ in epithelial cells. This 
might account for the protective phenotype of Vanin-1–de-
fi  cient mice against colitis. The absence of Vanin-1 and the 
consequently decreased levels of cysteamine in tissue will 
promote PPARγ antiinfl  ammatory eff  ects by inhibition of 
the transcription of epithelial signals intended to alert the 
  innate eff  ectors of the mucosal immune system. Our data 
support the idea that the presence of Vanin-1 at the epithelial 
level is determinant for the perception of stress by innate 
  immune cells. Thus, targeting infl  ammatory pathways in epi-
thelial cells might help to control the development of colitis. 
Finally, the manipulation the Vanin-1/pantetheinase activity 
represents an attractive therapeutic strategy for the treatment 
of IBD.
MATERIAL AND METHODS
Mice. Mice were kept in a specifi  c pathogen-free mouse facility and handle 
according to the rules of Décret no. 87–848 du 19/10/1987, Paris. All experi-
ments were performed on 6–8-wk-old Vanin-1−/− mice or WT BALB/c lit-
termate controls. Vanin-1−/− lymphocyte-defi  cient mice used for experiments 
were generated by introducing the Vanin-1 defi  ciency on a BALB/c SCID 
background. To generate chimeras, Vanin-1−/− and BALB/c mice were total 
body irradiated (10 Gy) before receiving 106 T cell–depleted bone marrow 
cells obtained from Vanin-1−/− or BALB/c donors.
TNBS-colitis. Acute colitis was induced by an intrarectal administration of 
100 μl containing 3 mg of TNBS (Sigma-Aldrich) in 30% ethanol. Cysta-
mine (Sigma-Aldrich) or BADGE (Sigma-Aldrich) treatments were per-
formed by a daily intraperitoneal administration of a 120 or 30 mg/kg dose, 
respectively, starting 2 d before TNBS treatment. Acute colitis was assessed 
2 d after infusion of TNBS. Colons were examined by two independent 
  individuals to evaluate the macroscopic lesions according to the Wallace 
  criteria (44). Colon tissue samples located precisely 2 cm above the anal canal 
were prepared for histological staining with hematoxylin and eosin. Histo-
logic grades were assigned in a blind manner by one pathologist according to 
the Ameho criteria (45).
Cytokine antibody array. Mouse cytokine antibody array membranes 
(RayBiotech) were incubated overnight at 4°C with 500 μg of total protein 
lysates prepared from colon tissues according to the manufacturer’s instruc-
tions. Detection of signal intensities was performed using a chemilumines-
cence imaging system (Intelligent Dark Box II; FUJIFILM). Relative cytokine 
expression levels were determined using the Multi Gauge V2.3 software 
(FUJIFILM). Internal controls included in the array were used to normalize 
the results from diff  erent membranes. Experiments were performed in dupli-
cate for each mouse genotype.
Mouse epithelial cell lines. MTE4.14 and mIC cells are Vanin-1–express-
ing mouse thymic epithelial cells and non-Vanin-1–expressing IECs, respec-
tively. We used a lentiviral-based strategy to generate both Vanin-1(+) mIC 
cells and MTE4.14-derived stable clones with   80% reduction of the cell JEM VOL. 203, December 25, 2006  2825
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surface expression of Vanin-1 by means of the RNA interference technol-
ogy (named herein MTE4.14-Vanin-1RNAi). In brief, full-length Vanin-1 
coding sequences were inserted into pRRLpgkEGFPsin18 (provided by D. 
Trono, University of Geneva, CH-1211, Geneva, Switzerland) by replacing 
the enhanced green fl  uorescent protein (EGFP) gene (pRRLpgkVanin1) 
(46). In parallel, Vanin-1 oligonucleotide encoding for shRNA was selected 
following the criteria described by Rubinson et al. (46) (5′-T  G  T  G  G  T  A  T-
C  T  A  T  G  C  A  C  C  C  G  A  T  T  C  A  A  G  A  G  A  T  C  G  G  G  T  G  C  A  T  A  G  A  T  A  C  C  A  C  T  T-
T  T  T  T  C  -3′ combined with the following complementary strand 3′-A  C  A  C-
C  A  T  A  G  A  T  A  C  G  T  G  G  G  C  T  A  A  G  T  T  C  T  C  T  A  G  C  C  C  A  C  G  T  A  T  C  T  A  T  G  G-
T  G  A  A  A  A  A  A  G  A  G  C  T  -5′) and placed under the control of the U6 promoter 
into the Lentilox 3.7 vector (LL3.7; provided by Luke van Parijs, Center for 
Cancer Research, Massachusetts Institute of Technology, Cambridge, MA) 
to generate LL3.7shRNAvanin1. Lentiviral particle stocks were produced 
according to a previously described protocol (46). Viral titers were assessed 
by quantifying the percentage of EGFP or Vanin-1(+) HUH7 target cells by 
fl  ow cytometry (FacsCalibur; Becton Dickinson). Membrane expression of 
Vanin-1 was assayed using the 407 monoclonal antibody (4). The lentiviral 
preparations showed viral titers ranging from 2 to 5 × 108 IU/ml. No rep-
lication competent virus was detected in any of viral stocks. MTE4.14 cells 
were transduced with LL3.7shRNAvanin1 or LL3.7 vector as control in a 
fi  nal volume of 500 μl of 8 μg/ml polybrene with a multiplicity of infec-
tion of 40. EGFP expression was used to sort transduced cell populations. 
We obtained one MTE4.14-Vanin-1RNAi clone showing a stable  80% 
reduction of the cell surface expression of Vanin-1. In parallel, mIC cells 
were transduced with pRRLpgkVanin1 or pRRLpgkEGFP as control using 
a multiplicity of infection of 100.
Real-time quantitative PCR. Total RNAs were prepared from tissue 
samples or harvested cell cultures using the TRIzol reagent (Invitrogen). 
Reverse transcription was performed using the QuantiTect Reverse Tran-
scription kit (Qiagen). Expression of mouse MCP-1, MIP-2, COX-2, and 
PPARγ mRNAs was measured by the real-time quantitative RT-PCR 
method using SYBR green Master Mix (ABI) and the ABI PRISM 7700 se-
quence detection system (PE Applied Biosystems). Relative mRNA levels 
were determined by the comparative threshold cycle (2-∆∆CT) method (47). 
The expression of all mRNAs was normalized to that of actin mRNA. All 
data shown here result from at least three independent experiments. Se-
quences of all primers used in this study are the following: MCP-1, forward 
5′-ctcacctgctgctactcattc-3′ and reverse 5′-gcttgaggtggttgtggaaaa-3′, MIP-2, 
forward 5′-accctgccaagggttgacttc-3′ and reverse 5′-ggcacatcaggtacgatccag-3′, 
COX-2, forward 5′-tcaaaagaagtgctggaaaaggtt-3′ and reverse 5′-tctacctgag-
tatctttgactgtg-3′, and PPARγ, forward 5′-gatgcaagggtttcttccggagaac-3′ and 
reverse 5′-tggtgatttgtctgttgtctttc-3′.
Western blot analysis. 30 μg of total protein lysates derived from either 
harvested epithelial cell cultures, colonic tissue samples, or purifi  ed IECs 
were loaded on SDS-PAGE gels. Membranes were probed overnight at 4°C 
with antibodies against PPARγ (Santa Cruz Biotechnology, Inc.), COX-2 
(Cayman), or actin (Sigma-Aldrich) antibodies followed by the appropriate 
species-specifi  c horseradish peroxidase conjugate (Sigma-Aldrich) and de-
veloped using the enhanced chemiluminescence detection system (GE 
Healthcare). Quantifi   cation of band intensities was performed using the 
Multi Gauge V2.3 software (FUJIFILM).
Isolation of IECs. Colons were cut open longitudinally, and feces was re-
moved by washing with PBS. Colons were then cut in small pieces (2 mm) 
and carefully rocked in RPMI 10% FBS solution for 10 min at 25°C. Colon 
pieces were then successively incubated under shaking in collagenase mix 
(RPMI containing 0.2 mg/ml collagenase, 20 mM Hepes, 2% FCS) for 
15 min at 30°C, collagenase mix supplemented with 0.2 mg/ml of dispase 
plus 25 μg/ml DNase I for 25 min at 30°C, and fi  nally trypsin mix (PBS 
containing 0.05% trypsin, 0.5 mM EDTA, 0.3% BSA, 50 μg/ml DNase I) 
for 25 min at 36°C. Resulting preparations were fi  ltered on cell strainers (BD 
Falcon) and centrifuged. Pelleted cells were then resuspended, and IECs 
were isolated from lymphoid cells using a gradient of Percoll. Cells were 
counted and checked for viability.
Luciferase reporter assay. The 3XPPRE-TK-luc plasmid (48) was pro-
vided by ADDGENE. MTE4.14 control and MTE4.14 Vanin-1RNAi 
clones were cultured in 24-well plates and cotransfected with 250 ng of 
3XPPRE-TK-luc plus 50 ng of pRL-TK-RN control vector (Promega) 
  using the lipofectamine 2000 (Invitrogen). 24 h later, cells were treated for 
12 h with 10 μM 15-d-PGJ2 (Sigma-Aldrich) alone or in combination with 
10 μM of ATRA (Sigma-Aldrich). After treatment, cells were lysed in PLB 
buff  er, and detection of the luciferase transcription was performed using the 
Dual luciferase assay kit (Promega).
PPAR𝗄 translocation. Vanin-1(+) and (−) mIC cells were seeded on 
coverslips in 24-well plates at a density of 2 ×105 cells/well. After 24 h, 
cells were transfected with 1 μg of GFP-tagged PPARγ plasmid (provided 
by J.P. Desreumaux, Institut National de la Santé et de Recherche Médi-
cale U795, Lille, France) using lipofectamine 2000 (Invitrogen). 24 h after 
transfection, cells were treated overnight with 20 μM of 15-d-PGJ2 (Sigma-
Aldrich) and then PBS washed and fi  xed in 4% paraformaldehyde. The 
nuclei were stained with DAPI (Sigma-Aldrich) after permeabilization of 
cells with 0.1% Triton X-100. Coverslips were mounted with mowiol 
and visualized with a Zeiss Axiovert fl  uorescence microscope (Carl Zeiss 
MicroImaging, Inc.).
Statistical analysis. Data are expressed as means ± SD. Values from exper-
imental and control groups were compared using the Student’s t test. Proba-
bility values of P < 0.05 were considered statistically signifi  cant.
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